![](/images/graphics-bg.png)
Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
المؤلفون المشاركون
Yajima, Hidetaka
Ishimine, Yu
Goto, Akira
Watanabe, Yoshito
Nakagaki, Suguru
Yabana, Takashi
Adachi, Takeya
Kondo, Yoshihiro
Kasai, Kiyoshi
المصدر
Case Reports in Gastrointestinal Medicine
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-03-29
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Trastuzumab has recently been introduced as a treatment for HER2-positive metastatic and/or unresectable gastric cancer (MUGC); however, compared with breast cancer, some issues concerning HER2 and trastuzumab therapy for gastric cancer remain unclear.
A 74-year-old woman received trastuzumab-containing chemotherapy for HER2-positive MUGC.
She had a marked response to 8 months of chemotherapy, and gastrectomy and hepatic metastasectomy with curative intent were performed.
The resected specimen showed complete loss of HER2 positivity in the residual tumor.
For MUGC, a change in HER2 status during the course of the disease with or without chemotherapy has rarely been reported.
However, in breast cancer, a significant frequency of change in HER2 status during the course of disease has been reported, and reevaluation of HER2 positivity in metastatic/recurrent sites is recommended.
The choice of trastuzumab for MUGC is currently based on the HER2 status of the primary tumor at the time of initial diagnosis, without reassessment of HER2 status during the course of disease and/or in metastatic/recurrent sites, on the assumption that HER2 status is stable.
However, our case casts doubt on the stability of HER2 in gastric cancer.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Ishimine, Yu& Goto, Akira& Watanabe, Yoshito& Yajima, Hidetaka& Nakagaki, Suguru& Yabana, Takashi…[et al.]. 2015. Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?. Case Reports in Gastrointestinal Medicine،Vol. 2015, no. 2015, pp.1-6.
https://search.emarefa.net/detail/BIM-1058527
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Ishimine, Yu…[et al.]. Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?. Case Reports in Gastrointestinal Medicine No. 2015 (2015), pp.1-6.
https://search.emarefa.net/detail/BIM-1058527
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Ishimine, Yu& Goto, Akira& Watanabe, Yoshito& Yajima, Hidetaka& Nakagaki, Suguru& Yabana, Takashi…[et al.]. Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?. Case Reports in Gastrointestinal Medicine. 2015. Vol. 2015, no. 2015, pp.1-6.
https://search.emarefa.net/detail/BIM-1058527
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1058527
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)